Korea Research Institute of Bioscience and Biotechnology

Yungjin Pharmaceutical Co., Ltd.

Korea Electric Power Corporation

Dongguk University Industry-academic Cooperation Foundation

Korea Western Power Co., Ltd.

Korea East-west Power Co., Ltd.

Korea Midland Power Co., Ltd.

Korea South Power Co., Ltd.

Korea Institute of Bioscience and Biotechnology

Doo-Young Kim

Sei-Ryang Oh

Ok-Kyoung Kwon

Jung-hee Kim

Dae-hee Shin

Byung-hwan Ryoo

Ji-seok Yoo

Yongnam Lee

Kyung-seop Ahn

Hyeongkyu Lee

Hyuk-hwan Song

Kyung Seop Ahn

Jung Hee Kim

Hyeong Kyu Lee

Hyung Won Ryu

Soo Hyun Kim

Kyeong Seok Lee

Sei Ryang Oh

Semi Kim

Jung Weon Lee

Su Ui Lee

Sangku Lee

Jung-Hwan Kim

Joongku Lee

Ha Young Jang

Hyun-Jun Lee

Jun-su Park

Hyuk-Hwan Song

Hyeong-Kyu Lee

Yong-Hee Jang

Ho-Jae Lee

Hyun-Ku Park

Su-Yong Choi

Soon-Ja Choi

Eun-Ah Kim

Kyungseop Ahn

Xuezhen Xu

In-Sik Shin

Kwang-Ha Park

Byung-Hwan Ryoo

Kyung-Seop Ahn

Ji-Seok Yoo

Dae-Hee Shin

Jung-Hee Kim

A bent rotor straightening method using low-frequency induction heating and a bent rotor straightening apparatus using the method are proposed. The bent rotor straightening method using low-frequency induction heating according to an embodiment of the present invention includes: calculating a heating speed when a first target temperature for correcting bending of a rotor using low-frequency induction heating is set; maintaining the first target temperature for a heating time determined on the basis of a diameter of the rotor when the first target temperature is reached, when performing primary thermal correction at the heating speed; checking whether a bending amount of the rotor reaches a predetermined critical value in accordance the result of performing the primary thermal correction; and finishing correction of bending of the rotor in accordance with the result of checking the bending amount of the rotor.

Bent rotor straightening method using low frequency induction heating and bent rotor straightening apparatus using same

A pharmaceutical composition includes any of an extract of, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-&#x3b1; and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

Pharmaceutical composition for preventing and treating chronic obstructive lung disease containing, as active ingredient,extract, fraction, or active fraction thereof

The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

2-phenylbenzofuran derivatives, method for preparing the same and use of the same for treating inflammatory disease

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract ofvarthan that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

[object Object]

A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract ofvarthan that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-&#x3b2;1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

Composition containing styraxlignolide A or the aglycone thereof as an active ingredient for preventing or treating asthma

The present invention relates to an anoikis-inducing agent comprising aextract, a tiarellic acid compound isolated therefrom or a pharmaceutically acceptable salt thereof, which is specific to cancer cells expressing a tumor-associated antigen L6 or a homolog thereof. Theextract, the tiarellic acid compound isolated therefrom or pharmaceutically acceptable salt thereof of the present invention leads to loss of cell adhesion to reduce cancer cell proliferation and exhibits the effect of inducing cell death in cancer cells expressing a tumor-associated antigen L6 or a homolog thereof, thereby being used for preventing and treating cancer diseases due to a tumor-associated antigen L6 or a homolog thereof.

Growing community of inventors

Daejeon, South Korea

Doo-Young Kim